Pregnancy

Pregnancy App Babyscripts Partners with Nuvo Group to Deliver a Comprehensive Remote Pregnancy Care Solution

Babyscripts, the virtual care platform for managing obstetrics, is partering with Nuvo Group, a company commercializing INVU by Nuvo, an FDA-cleared, prescription-initiated, remote pregnancy monitoring platform. This collaboration will offer non-stress tests by INVU, within Babyscripts’ commercial ecosystem, with the singular goal of advancing pregnancy care delivery for providers and their patients, particularly those at high risk for complications. Babyscripts Virtual Maternity…

Amma Pregnancy Tracker Raises $2M to Invest in Growth and Internationalization

Amma pregnancy tracker, a mobile app providing pregnant women and their families evidence-based content, pregnancy health tracking, and personalized advice from professional obstetricians and gynecologists, has raised a $2M pre-Series A round to invest in growth and internationalization. New investors in this recent round include Alexey Solovyov A. Partners, the Joint Journey investment office Sergey Dashkov, the Angelsdeck business angel club, as…

Progenity Announces a New Patent Granted for Its Preeclampsia Rule-Out Test

Biotech company Progenity has announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,112,403 for assessment of preeclampsia using assays for free and dissociated placental growth factor to the company. The patent is directed to methods, compositions, and kits for detecting and measuring free and dissociated placental growth factor (PlGF) levels in biological samples. PlGF is…

Pregnancy After Loss Support (PALS) Launches a New App to Support Parents Conceiving After Child Loss

Pregnancy After Loss Support (PALS), a non-profit organization and community support resource for pregnancy after loss, today announced the launch of its first mobile app, the Pregnancy After Loss App, which will provide support to women and their partners experiencing the grief of miscarriage during a subsequent pregnancy. Pregnancy after loss is a unique blend of grief and joy. A 2015 study found…

Pregnancy App Babyscripts Announces a New Collaboration with Privia Health

Babyscripts, the virtual care platform for managing obstetrics, is partnering with Privia Health, a technology-driven, national physician enablement company that collaborates with medical groups, health plans and health systems. Through this collaboration, Privia Health will sponsor the use of Babyscripts to their providers across the nation, enabling physicians with Privia Women’s Health to deliver pregnancy care to their pregnant and postpartum patients.…

Medical Device Company Materna Medical Raises $10M to Accelerate Growth

Materna Medical, a clinical-stage medical device company, has announced the completion of a $10 million Series A2 financing round. The round was led by Wavemaker Three-Sixty Health (Wavemaker 360) with new investors including Kimera Limited, Women’s Venture Capital Fund, Golden Seeds, Black Capital, Shatter Fund, and Astia Angels. Key existing investors also joined the syndicate including Band of Angels, Texas Halo Fund,…

Femtech Company Elvie Raises a £58M Series C to Invest in Product Development and Growth

Leading UK-based femtech company Elvie has just announced the closing of a £58M Series C. The round was led by BFG with participation from funds and accounts managed by BlackRock, a consortium including Hiro Capital and Westerly Winds, Octopus Ventures and PPGL. Elvie was founded in 2013 by Tania Boler. Its current product line-up includes Elvie Trainer, an app-connected Kegel trainer, Elvie…

Organon and ObsEva Enter Global License Agreement for Preterm Labor Treatment

Every year, an estimated 15 million babies are born preterm. Organon, a global women’s health company spun out of Merck and ObsEva, a biopharmaceutical company dedicated to improving women’s reproductive health have now announced that the companies have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant (OBE022). Ebopiprant is an investigational, orally active,…